A new trading day began on Tuesday, with Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) stock price remained unchanged from the previous day of trading, before settling in for the closing price of $14.30. RDY’s price has ranged from $12.90 to $16.89 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 8.97%. Meanwhile, its annual earnings per share averaged 2.14%. With a float of $834.06 million, this company’s outstanding shares have now reached $834.38 million.
Let’s determine the extent of company efficiency that accounts for 27048 employees. In terms of profitability, gross margin is 59.29%, operating margin of 22.52%, and the pretax margin is 24.1%.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Dr. Reddy’s Laboratories Ltd. ADR is 0.00%, while institutional ownership is 14.46%. The most recent insider transaction that took place on Jul 29 ’24, was worth 5,390,000.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of 16.64 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 16.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.74% during the next five years compared to 20.07% growth over the previous five years of trading.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) Trading Performance Indicators
Here are Dr. Reddy’s Laboratories Ltd. ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.36. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.32. Likewise, its price to free cash flow for the trailing twelve months is 87.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.77, a number that is poised to hit 0.22 in the next quarter and is forecasted to reach 0.82 in one year’s time.
Technical Analysis of Dr. Reddy’s Laboratories Ltd. ADR (RDY)
Looking closely at Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY), its last 5-days average volume was 1.64 million, which is a jump from its year-to-date volume of 1.06 million. As of the previous 9 days, the stock’s Stochastic %D was 63.70%. Additionally, its Average True Range was 0.26.
During the past 100 days, Dr. Reddy’s Laboratories Ltd. ADR’s (RDY) raw stochastic average was set at 12.64%, which indicates a significant decrease from 47.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 19.34% in the past 14 days, which was lower than the 20.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.15, while its 200-day Moving Average is $15.16. However, in the short run, Dr. Reddy’s Laboratories Ltd. ADR’s stock first resistance to watch stands at $14.37. Second resistance stands at $14.43. The third major resistance level sits at $14.54. If the price goes on to break the first support level at $14.20, it is likely to go to the next support level at $14.09. Should the price break the second support level, the third support level stands at $14.03.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) Key Stats
With a market capitalization of 11.93 billion, the company has a total of 834,701K Shares Outstanding. Currently, annual sales are 3,350 M while annual income is 668,000 K. The company’s previous quarter sales were 953,930 K while its latest quarter income was 149,380 K.